Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Molecular Partners Ag ADR (MOLN)

Molecular Partners Ag ADR (MOLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

MOLN : 4.10 (+3.42%)
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

MOLN : 4.10 (+3.42%)
Molecular Partners to hold three poster presentations at AACR 2025

MOLN : 4.10 (+3.42%)
Molecular Partners Publishes Invitation to Annual General Meeting 2025

MOLN : 4.10 (+3.42%)
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

MOLN : 4.10 (+3.42%)
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

MOLN : 4.10 (+3.42%)
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

MOLN : 4.10 (+3.42%)
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

MOLN : 4.10 (+3.42%)
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

MOLN : 4.10 (+3.42%)
Molecular Partners AG Reports Acceptable Safety Profile and Initial Efficacy Data for MP0533 and MP0621 at ASH 2024

Molecular Partners updates on MP0533 and MP0621 studies, showing acceptable safety and initial efficacy in ongoing clinical trials.Quiver AI SummaryMolecular Partners AG announced continued progress in...

MOLN : 4.10 (+3.42%)

Barchart Exclusives

Trade Deals, CPI and Other Can't Miss Items this Week
The stock market continued its recovery last week, building on momentum from the Federal Reserve's policy decision. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar